Trial Profile

A Pilot Prospective Trial Of Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin [doxorubicin liposomal] Or Topotecan In Recurrent Or Persistent Ovarian Cancer Within 12 Months Of Platinum-Based Chemotherapy.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 11 Oct 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Feb 2011 Planned end date changed from 1 Jan 2010 to 1 Oct 2009 as reported by ClinicalTrials.gov.
14 Oct 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
14 Oct 2009 Planned end date changed from 1 Aug 2011 to 1 Jan 2010 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com